Metformin in Breast Cancer, Visualized With Positron Emission Tomography
- Conditions
- Breast Cancer
- Interventions
- Radiation: 11C-metformin
- Registration Number
- NCT02882581
- Lead Sponsor
- Aarhus University Hospital
- Brief Summary
The general purpose of the trial is to investigate whether metformin is taken up into the breast tumor. Studies in the last few years have shown an effect of metformin on cell proliferation on breast cancer. It is though unclear whether the effect on tumor is direct, indirect or a combination of the two. The investigators plan to:
* investigate if metformin is taken up in breast cancer using our novel 11C-metformin tracer and positron emission tomography (PET)
* investigate whether the uptake is correlated to the amounts of organic cation transporters (OCT1-3, MATE 1 \&2 and PMAT) using quantitive polymerase chain reaction (qPCR).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 7
- over 50 years
- C. mammae
- Tumor size: > 10 mm in diameter
- Unilateral cancer
- WHO performance status 0-1
- Severe heart- or kidney failure
- Pregnant or breast feeding
- If the patient is found not eligible for participation in the study på principal investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 11C-metformin 11C-metformin All participants allocated to the study will be included in this arm
- Primary Outcome Measures
Name Time Method Metformin uptake in breast cancer 12 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Department of Nuclear Medicine & PET-center, Aarhus University Hospital
🇩🇰Aarhus, Denmark
Department of Surgery, Aarhus University Hospital
🇩🇰Aarhus, Denmark